Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
What does a seven-year old trademark application, filed by the CEO, have to do with CRXM?
This is not an uncommon occurrence, and is totally unrelated to a discussion of Gene Biotherapeutics.
An application for a trademark is not necessarily indicative of a business project, and even if it was the implication that a person cannot pursue another interest while running a public company is a totally flawed assumption.
We doubt that they would have even mentioned it in the Super 10-K without at least having some sort of preliminary understanding of the potential for Generx to help with these kinds of heart-related effects from COVID jabs.
We won't try to front-run the company on this. If and when they have updates or news regarding next steps, e.g. funding, clinical studies, etc. they will likely make an announcement publicly.
In the meantime, investors may want to take this information presented in the Super 10-K (which, unfortunately, very few retail investors even bother to read) when assessing the potential investment merits of CRXM.
It's important to consider the broader applications for CRXM's Generx drug therapy, as well as the application for those suffering from refractory angina.
Could it be the start of another leg up?
The short-sellers are trying to create a narrative to push the shares down.
So far, it's not working.
The REALITY is that the stock continues to climb higher and higher.
We feel badly for the shorts (NOT!!!!!).
We would never begrudge a CEO who has done such a phenomenal job of building shareholder value the opportunity to sell a few shares in order to capture some of the record run in the price of the stock.
Mr. Fieldly has never sold a single share of CELH stock until this recent filing.
His is certainly entitled to reap the rewards of years of hard work in building the Celsius brand.
He has made a lot of people extremely wealthy as a result of his success in leading this company to where it is today.
We say congratulations on a job well done, along with a heartfelt “thank you” to Mr. Fieldly.
Funny how it's always easy to spot a desperate short-seller.
We are not disputing the facts, just your interpretation of them.
It is not uncommon for insiders to lighten up after a huge increase in share price.
Besides, there are other investors acquiring the shares that are being sold by insiders, so the impact that will be felt in the market is negligible.
Calling this a coordinated dumping of shares, is taking a normal activity in the capital markets to a level beyond what is a very common occurrence on Wall Street.
It really no big deal, unless someone happens to be short.
It's doubtful that they would have put this in the Super 10-K if they were not actively exploring potential applications.
This could potentially be a huge wildcard, and alone could significantly impact the awareness of the company by investors.
Angiogenic Research Initiative for COVID-19.
Early research has provided evidence of respiratory, neurological, and cardiac abnormalities in patients who have had severe COVID-19 immunological response requiring acute care (including protracted hospitalization and the need for mechanical ventilation). For patients who have survived and seek to return to normal life, several continuing residual adverse medical conditions appear to persist.
While the scientific literature remains uncertain, it has been suggested that mechanisms by which COVID-19 could lead to cardiovascular morbidity include direct myocardial injury as a result of inflammatory cascade or cytokine release, acute coronary syndrome from acute inflammation-triggered destabilization of atheroma, microvascular damage due to disseminated intravascular coagulation and thrombosis, direct entry of SARS-CoV-2 into myocardial cells via ACE2 receptors, and hypoxemia combined with metabolic demands of acute illness leading to myocardial injury akin to a myocardial infarction.
Based on these preliminary insights, Gene Biotherapeutics’ research is focused on the design of an observational clinical study to evaluate if COVID-19 may exacerbate microvascular damage and perfusion impairment in patients with pre-existing coronary artery disease and cardiac reversible perfusion defects (“RPD”) prior to COVID-19 infection. We are proposing to assess the damage using SPECT (Single-Photon Emission Computed Tomography) imaging to evaluate changes in RPD as a result of COVID-19 infection. Demonstration of worsening perfusion due to COVID-19 would be supportive of the potential to evaluate the therapeutic benefit of the Generx [Ad5FGF-4] product candidate angiogenic gene therapy in this patient population.
There is so much more for ALLM to focus on besides ethanol.
https://www.research.fsu.edu/research-offices/oc/technologies/lignin-based-biodegradable-plastic/
https://www.anthropocenemagazine.org/2021/04/bioplastic-made-from-wood-powder-is-durable-yet-fully-biodegradable/
https://www.abc.net.au/radionational/programs/scienceshow/lignin-a-possible-basis-for-new-bioplastics/11575182
The total addressable market (TAM) for biodegradable plastics is enormous.
https://www.marketsandmarkets.com/Market-Reports/biopolymers-bioplastics-market-88795240.html?gclid=Cj0KCQjw5auGBhDEARIsAFyNm9E0ZPx6NR4cf2RSKH-Su-j3A-e8Xd0DTLAHye2WJIXLEos9fE5Ufq4aAmqKEALw_wcB
The OTC Market is like the Wild Wild West.
It is difficult to discern what is really going on in terms of the trading patterns in CRXM, and quite frankly we could care less.
We took a substantial position in CRXM based on the long-term potential for Generx, and the promising results seen in the first two clinical trials.
All of this speculation and guessing at what is going on, e.g. short-selling, dilution, de-listing of the company stock by the end of September, etc. etc. is all just wasted energy.
The individual(s) who keeps posting about big news coming any day now reminds us of the little boy who cried wolf.
We avoid the noise and stay focused on the long-term fundamental story.
Micro-cap investing requires patience, patience and more patience.
We saw CELH go from less than $0.50 cents when we first wrote about it on Seeking Alpha back in 2015 to over $80.00 recently.
Similarly, GLUC went from roughly $0.14 cents when we first wrote about the company on our blog page back on April 5, 2017 to almost $9.00 this past January.
These were huge gains for micro-cap investors.
We expect no less for CRXM.
Not sure what you are driving at. There was nothing unethical involved.
It’s highly unlikely that the pending doom that you are suggesting will ever take place.
Do you really think that management and Nostrum will let that happen?
You are simply attempting to sow seeds of doubt in order to frighten investors into selling their shares.
Not making fun of anyone. Every investor hopes that they will profit from their investments.
The problem is when the same information gets posted ad nauseum, without any real basis other than speculation and conjecture, it appears to border on pumping.
We hope that Bentley is ultimately proven correct, but to come on here day after day and post the same information serves no useful purpose.
That’s because the price is out of reach for many investors on I-HUB.
It is more likely that Sabby's 15 million shares are already included in the 49 million number.
As indicated earlier, a shareholder must use the latest numbers from the most current public filing in determining whether or not they are required to file a share ownership disclosure document with the SEC.
You don't get to make assumptions. You must file based on the facts made public in the Super 10-K from April 23 2021.
A couple of other things that you may want to take notice of:
Even if you have already filed based on owning a 5% or greater stake, you are required to make an updated and amended filing "promptly", i.e., within 2 business days regarding any material change in ownership.
If you cross the 10% ownership threshold, you are the considered to be an "affiliate" of the company and a whole new set of onerous SEC rules will apply, including a provision that allows the company (or any shareholder of the company) to seek a legal remedy which can lead to the 10% shareholder having to disgorge any profits received from the sale of those same securities within 6 months of their original purchase date.
Subject to limited exceptions, the purchase and sale, or sale and purchase, of equity securities within a period of less than six months will result in “matchable” transactions under Section 16 of the 1934 Act.
The highest sale price will be matched against the lowest purchase within that period to determine if the insider received “short-swing profits.” This formula can result in deemed profits, even if you lost money on the transactions. If there is a matching transaction, you would be required to disgorge any such short-swing profits to Gene Biotherapeutics.
Note that Gene Biotherapeutics cannot waive its right to recover the short-swing profits, and any GB stockholder can bring suit in GB’s name to recover short-swing profits on behalf of GB.
Also, Section 16 imposes a strict liability standard—good faith mistakes or misunderstandings of the law are not defenses.
Bentley and JJ24,
You both need to be very careful about what you disclose on a public message board regarding your share position.
At both the 5% and 10% ownership thresholds, you will need to submit a filing of SEC Form 3 or 4 and Form 13D/G.
DO NOT think that because the exact share count is unknown at this point it absolves you from these filing requirements.
Irrespective of any further potential dilution, you must file using the last publicly available number of shares outstanding from the company's latest filing dated 4/23/2021 which shows 49,622,154 shares.
At this point, if any shareholder holds more than 2,482,000 (5% ownership) or 4,963,000 (10% ownership) they are required to file with the SEC.
The fact that you are announcing this on a public message board only exacerbates any potential problems you might face by not filing with the regulators.
This should be taken very seriously. The consequences of running afoul of any SEC regulations are severe.
Please use common sense and follow the rules, or you may be risking legal action.
It's highly unlikely that Nostrum is going to let that happen.
Do you really believe that they went through all of the trouble to get the Super 10-K filed, only to drop the ball on the other filing requirements?
It seems that the only reason that you are here is to sow seeds of doubt and stir up trouble.
Yet, you have indicated that you would buy shares at $0.03 cents.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=163522817
You are talking out of both sides of your mouth. Wonder why?
Does it really matter?
To pose a question like that, you must be under the delusion that you are somebody of importance.
From the tone and tenor of your posts, you sure don’t sound very important to us.
Besides, if you were important, the CEO and/or CFO would most likely take your call. But, since you claim that they aren’t speaking to you, that casts your claim of being important into doubt.
Don’t expect bird brain to take the initiative to do anything other than constantly complain.
The company has said that its future plans are to become a fully-reporting SEC company, with audited financials, and to up-list to the OTCQB, with the intention of ultimately meeting the requirements for listing on a national exchange.
When those two things will happen is the big question for investors.
<<"It is our intention to become current, and we are preparing quarterly reports for the periods ended March 31, June 30, and September 30, 2020.">>
<<"Our common stock currently is listed only on the OTC Pink Sheets. We hope to have our Common Stock re-established on the OTC QB once our SEC filing delinquencies are rectified. OTC QB is a reporting service and not a securities exchange. It is our intent to secure a listing on the Nasdaq Capital Market or another National Exchange, but we do not currently meet the listing criteria and we may never qualify for trading on a national exchange.">>
https://www.otcmarkets.com/filing/html?id=14889579&guid=u6InUqXbKHnEl3h
Yes, you are correct.
We hold substantial share positions in all of our micro-cap ideas, but none bigger than ALLM.
It is our #1 micro-cap pick for 2021
https://seekingalpha.com/article/4397491-blue-biofuels-absolute-best-and-no-1-microcap-idea-for-2021
We view that scenario as highly-unlikely. That kind of dilution would be irresponsible and damaging to the capital structure.
<<"By the time any real news hit, they will dilute it to 500m shares+">>
Also, in the past, we have become accustomed to dealing with all of the negative chatter on the I-HUB boards. It doesn't faze us, and shouldn't be given much consideration by investors.
Our two other micro-cap picks (CELH and GLUC) produced phenomenal returns for investors.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=162688791
Would you label us as being dreamers with these stocks too?
<<"Amazing how dreamers still think this will go above 10c">>
We would certainly agree that returns topping 15,900% and 6,300% are something that most investors can only dream of, but they are achievable with the right combination of talent, hard work, and a little bit of luck.
We should note that CELH and GLUC were our only two micro-cap ideas in our first 6 1/2 years on Seeking Alpha.
CRXM is going to be another big winner, in our opinion.
Don't let the day-to-day noise cause you to take your eye off the ball.
Short-term traders can have the pennies. Long-term investors will reap the rewards of their vision and patience in much larger sums.
You can choose to dismiss us, out of hand, if you wish, but you might want to do a bit more research on Altitrade Partners, before you do.
Good Luck to you.
A simple question.
The terms of the restructured notes are that the noteholders are to be paid from future revenues and profits, within 5 years, right?
And if the notes are not paid by then, they are cancelled.
Why would debt holders agree to those terms?
Put on your thinking caps now.
A couple of things stand out.
The balance sheet looks much improved after the recent capital raise.
Total current assets = $2,518,818
Total current liabilities = $454,338
That gives the company a current ratio of 5.5-to-1
More importantly, people seem to have missed this in the past few reports. At least, no one has yet to mention it. Probably since most investors don't read the Q's and K's all that closely.
The bulk of the long-term liabilities, in the form of debt on the balance sheet, is related to the notes payable. What many don't realize is that in the Chapter 11 negotiations, the company was able to restructure that debt to be paid solely from future revenues and profits.
Furthermore, if the notes are not paid within a 5-year period from exiting Chapter 11 bankruptcy (September 18, 2019), the notes will be discharged.
In essence, the debt would get wiped out, and taken off the books.
Of the $2,854,462 due as of March 31, 2021, $2,738,132 is due out of future revenue or future profits. $2,417,502 of the $2,854,462 will be discharged if not paid by September 18, 2024, which is 5 years after the Company exited Chapter 11. $66,330 has be forgiven by the SBA in April, 2021. The remaining debt that would not be discharged or forgiven is $370,630, consisting of $200,630 due to related parties, and $120,000 due to other, and a $50,000 Chapter 11 settlement.
This was a major win for the company in the Chapter 11 negotiations.
Too bad, it seems to have escaped the attention of most everyone.